JP7695773B2 - 新規化合物及びそれらの治療上の使用 - Google Patents

新規化合物及びそれらの治療上の使用 Download PDF

Info

Publication number
JP7695773B2
JP7695773B2 JP2019554924A JP2019554924A JP7695773B2 JP 7695773 B2 JP7695773 B2 JP 7695773B2 JP 2019554924 A JP2019554924 A JP 2019554924A JP 2019554924 A JP2019554924 A JP 2019554924A JP 7695773 B2 JP7695773 B2 JP 7695773B2
Authority
JP
Japan
Prior art keywords
nhco
antibody
formula
immunoconjugate
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019554924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516613A5 (enExample
JP2020516613A (ja
Inventor
ウェストビー マイケル
グロソップ メラニー
ワトソン クリスティン
ピックフォード クリストファー
Original Assignee
センタウリ セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センタウリ セラピューティクス リミテッド filed Critical センタウリ セラピューティクス リミテッド
Publication of JP2020516613A publication Critical patent/JP2020516613A/ja
Publication of JP2020516613A5 publication Critical patent/JP2020516613A5/ja
Priority to JP2023066568A priority Critical patent/JP2023100679A/ja
Application granted granted Critical
Publication of JP7695773B2 publication Critical patent/JP7695773B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019554924A 2017-04-07 2018-04-06 新規化合物及びそれらの治療上の使用 Active JP7695773B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023066568A JP2023100679A (ja) 2017-04-07 2023-04-14 新規化合物及びそれらの治療上の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1705686.2A GB201705686D0 (en) 2017-04-07 2017-04-07 Novel compounds and therapeutic uses thereof
GB1705686.2 2017-04-07
PCT/GB2018/050928 WO2018185495A1 (en) 2017-04-07 2018-04-06 Novel compounds and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023066568A Division JP2023100679A (ja) 2017-04-07 2023-04-14 新規化合物及びそれらの治療上の使用

Publications (3)

Publication Number Publication Date
JP2020516613A JP2020516613A (ja) 2020-06-11
JP2020516613A5 JP2020516613A5 (enExample) 2021-04-30
JP7695773B2 true JP7695773B2 (ja) 2025-06-19

Family

ID=58744828

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019554924A Active JP7695773B2 (ja) 2017-04-07 2018-04-06 新規化合物及びそれらの治療上の使用
JP2023066568A Pending JP2023100679A (ja) 2017-04-07 2023-04-14 新規化合物及びそれらの治療上の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023066568A Pending JP2023100679A (ja) 2017-04-07 2023-04-14 新規化合物及びそれらの治療上の使用

Country Status (12)

Country Link
US (1) US11766483B2 (enExample)
EP (1) EP3606561B1 (enExample)
JP (2) JP7695773B2 (enExample)
KR (1) KR102646581B1 (enExample)
CN (1) CN110753558B (enExample)
AU (1) AU2018248706B2 (enExample)
CA (1) CA3059018A1 (enExample)
ES (1) ES2954294T3 (enExample)
GB (1) GB201705686D0 (enExample)
IL (1) IL270460B2 (enExample)
WO (1) WO2018185495A1 (enExample)
ZA (1) ZA201906580B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512438A (ja) 1997-02-11 2001-08-21 イムノメディクス，インコーポレイテッド αガラクトシルエピトープで標識された抗体による免疫応答の刺激
JP2007527419A (ja) 2004-01-09 2007-09-27 キャリー ビー． マリス、 化学的にプログラム可能な免疫

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2801305B1 (fr) 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
FI20011664L (fi) 2001-08-17 2003-02-18 Carbion Oy Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
JP2005535723A (ja) 2002-08-20 2005-11-24 バイオティ セラピィーズ コープ 腫瘍特異的オリゴ糖エピトープおよびその用途
US7585886B2 (en) * 2005-05-19 2009-09-08 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
CN105709237A (zh) * 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
US20100173323A1 (en) * 2006-06-09 2010-07-08 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
WO2009134891A2 (en) * 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
CA2716622A1 (en) 2008-02-26 2009-09-03 The Regents Of The University Of California Glycopeptides and methods of making and using them
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
JP6111276B2 (ja) * 2012-03-17 2017-04-05 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ コンホメーション制約された全合成されたマクロ環化合物
US9556167B2 (en) * 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
AU2015282627B2 (en) * 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
GB201517859D0 (en) * 2015-10-08 2015-11-25 Altermune Ltd Novel compounds and therapeutic uses thereof
US11014966B2 (en) * 2016-09-13 2021-05-25 Centuari Therapeutics Limited Compounds and therapeutics uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512438A (ja) 1997-02-11 2001-08-21 イムノメディクス，インコーポレイテッド αガラクトシルエピトープで標識された抗体による免疫応答の刺激
JP2007527419A (ja) 2004-01-09 2007-09-27 キャリー ビー． マリス、 化学的にプログラム可能な免疫

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Il Farmaco Ed. Sc., 1973, vol. 28, no. 7, pp. 511-522
J. Indian Chem. Soc., 1987, vol. 64, no. 1, pp. 34-37
J. Org. Chem., 1981, vol. 46, no. 20, pp. 3949-3953

Also Published As

Publication number Publication date
KR20200018402A (ko) 2020-02-19
EP3606561A1 (en) 2020-02-12
GB201705686D0 (en) 2017-05-24
IL270460B2 (en) 2023-09-01
CN110753558B (zh) 2023-10-24
JP2023100679A (ja) 2023-07-19
AU2018248706A1 (en) 2019-11-07
ZA201906580B (en) 2024-01-31
IL270460B1 (en) 2023-05-01
CN110753558A (zh) 2020-02-04
KR102646581B1 (ko) 2024-03-13
AU2018248706B2 (en) 2022-04-07
EP3606561C0 (en) 2023-08-02
IL270460A (enExample) 2019-12-31
US20200147236A1 (en) 2020-05-14
JP2020516613A (ja) 2020-06-11
CA3059018A1 (en) 2018-10-11
US11766483B2 (en) 2023-09-26
ES2954294T3 (es) 2023-11-21
WO2018185495A1 (en) 2018-10-11
EP3606561B1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
US20220323596A1 (en) Antibody conjugates of toll-like receptor agonists
CN113164618A (zh) 用免疫刺激性缀合物治疗疾病的方法和组合物
JP2024150440A (ja) 化合物及びその治療的使用
JP2018531287A6 (ja) 化合物及びそれらの治療用途
JP2018531287A (ja) 化合物及びそれらの治療用途
JP2023100679A (ja) 新規化合物及びそれらの治療上の使用
US12350348B2 (en) Compounds and therapeutic uses thereof
HK40023976B (en) Novel compounds and therapeutic uses thereof
HK40023976A (en) Novel compounds and therapeutic uses thereof
EP3606558B1 (en) Novel compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230414

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230421

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230425

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250609

R150 Certificate of patent or registration of utility model

Ref document number: 7695773

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150